Seroctin helps the body make its own natural serotonin

Real Dream-Catchers teach the wisdoms of the Seventh Fire, an Ojibwe Prophecy, that is being fulfilled at this moment. The Light-skinned Race is being shown the result of the Way of the Mind and the possibilities that reside in the Path of the Spirit. Real Dem-Catchers point the way.

The compounds of the invention may be administered orally in the form of tablets, capsules, suspensions, solutions or other means suitable for such ingestion, perhaps as an admixture with other compounds to enhance absorption into the blood stream or to otherwise assist in achieving the desired effects.

The compounds of the invention may also be administered parenterally, as a subcutaneous, intramuscular or intravenous injection, or by way of an implant for sustained release. When administered parenterally, the compounds of' the invention are to be dissolved in physiologically acceptable liquid media and/or otherwise compounded in accordance with the known pharmaceutical art. Another mode of administering the compounds of the invention may be a transdermal patch, in which entry of the compounds of the invention into the body is facilitated via acceptable carrier molecules.

Unless otherwise defined, the technical and scientific terminology used herein has the same meaning as understood by those informed of the art to which this invention belongs.

Examples
Described herein are preferred or representative materials and methods for the practice of the invention. The materials and methods, along with the examples, are only illustrative in the sense that these are not intended to be limiting.

Example 1
The Similar Physiological Effects of the Compounds of the Invention
Representative compounds of Formulas1, 1I, and111 are shown in FIG. 2. That compounds of Formulas1, II and 111 have like physiological properties, and as such can be considered as similar or equivalent for therapeutic purposes, was tested via a rodent model.

Female montane voles, Microtis montanus, received intraperitoneal injections of representative compounds belonging to Formulas1, II and MI, and shown in FIG. 2, for three consecutive days and sacrificed 24 hours after the last injection to examine uterine weight response. To assess the properties of each representative compound, pure ones made by chemical means (University of Utah Department of Chemistry, Salt Lake City, UT) were prepared specifically for this test. All compounds were injected at a dose level of 5ug/day, dissolved in 5% propylene glycol for a total injection volume of 0. 5ml. Control animals received 0. 5ml of 5% propylene glycol only. All voles were 4-5 weeks old and weighed 25-29 g.

All compounds belonging to FormulasI, II and III caused a statistically significant increase in uterine weights (FIG. 3). On average, the uterine weight in voles receiving these was 22. 8 g, 50% greater than for the control group. The greatest average weight increase, 82% more than the uterine weight for the control voles, was in those females administered6-methoxy-2-benzoxazolinone, but even the least effect of a compound belonging to
Formulas1, 11 or 111, that for5-methoxy-2-benzoxazolinone, entailed a 32% increase in uterine weight. The results show that physiological effects or modes of action are held in common by the compounds of the invention.

Example 2
Compounds of the Invention as an Antidepressant and Aphrodisiac in Human Males

This component of the invention relates to a method for lessening depression and otherwise bettering mood or feelings of well-being, said method comprising the administration to human males of an effective amount of one or more of the compounds of the invention, defined above and in FIG. 1. This component of the invention also relates to a method for treating sexual dysfunction or otherwise increasing sexual desire and performance, including but not necessarily limited to lacking interest in sex, problems with arousal, not enjoying sex, and anxiety about sexual performance, said method comprising the administration of an effective amount of one or more of the active compounds of the invention.

A double-blind crossover study was done on human males to test compounds of the invention as a therapeutic agent for treating depression or otherwise elevating mood as well as bettering sexual function. The trial had three phases, each two weeks in duration, during which participants took compounds of the invention for one phase or two weeks. The daily dose was made up from compounds of the invention naturally contained in the ground leaves from immature corn plants, 30-45 cm tall, standardized with synthesized 6-methoxy-benzoxazolinone, to a total of15-mg 6-methoxy-2-benzoxazolinone. A dose of15-mg was selected because this was considered a likely minimum effective daily amount for humans, extrapolated from prior studies on rodents, rabbits and other animals. Previous anecdotal trials on humans done by the inventors suggested that a 15-mg daily dose had a desirable effect, but no adverse consequences to health.

Weekly assessments of depression or mental well being and sexual function were done via widely accepted indices : to quantify depression and generalized anxiety disorders, the Hospital Anxiety and Depression Scale (HAD) ; and for sexual desire, psychological arousal, and overall sexual outlook, the Arizona Sexual Experience Index (ASEX).

Phase One lasted 14 days, during which participants took daily doses of the invention or a placebo. Assignation of the invention or placebo to male participants was done randomly. Immediately prior to the 14 days comprising Phase One, an initial physical examination and blood analysis were done. At that time, each male filled out HAD and ASEX forms to assess mental well being and sexual function, was checked for sitting and standing blood pressure and pulse, and gave the blood sample needed for the biochemical analyses.

Phase Two consisted of a seven-day period immediately after Phase One, during which neither invention nor placebo was taken. During Phase Two, physical examination and laboratory analyses were again done. In Phase Three which lasted 14 days, participants again took either invention or a placebo. Assignation of the invention or placebo was done according to the sort of capsule taken during Phase One. If a participant took a compound of the invention in Phase One, then placebo was administered during Phase Three, and vice versa. Immediately after finishing Phase Three, a physical examination and laboratory analyses were again done. After completing Phase Three, each participant was asked prepared questions as well as solicited for any comments and impressions concerning invention use.

The results are tabulated in FIG. 4, and these indicate that the compounds of the invention have significant positive effect on depression or mood. Fourteen of the 15 participants properly completed the study and only data for these individuals were used for analysis. HAD scores exceeding 20. 0 denote clinical depression, but lower ones can also be associated with dispirited mood. Only two males entered the trial with HAD values exceeding the clinical minimum (21. 0 and 23. 0). Still, 12 of 14 subjects showed bettered mood, improved feelings of well being or lessened depression after taking compounds of the invention. Decreases in HAD scores over the two-week time span were as much as 15 and averaged 5. 2. The two clinically depressed subjects showed decreases in HAD values of 5. 0 and 15. 0. The average HAD score went from 13. 5 at the onset of the study to 9. 1 after two weeks of taking compounds of the invention, very significant statistically. Participants showed no statistically detectable changes while taking placebo.

1 - 2 - 3 - 4 - 5

Seroctin is a unique and effective PATENTED raw material that can greatly assist with the delicate process of balancing, distribution and reception of serotonin and other complimentary neurotransmitters.

In a world of exponentially increasing workloads and responsibilities, Seroctin truly is the right product, at the right time.

Disclaimer: The statements on www.real-dream-catchers.com  have not been evaluated by the FDA. These dream catchers are not intended to diagnose nor treat nor cure any disease or illnes

© 2007, Allen Aslan Heart / White Eagle Soaring
of the Little Shell Pembina Band, aTreaty Tribe of the Ojibwe Nation.